Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Pro Medicus Limited ( (AU:PME) ).
Pro Medicus Limited has secured a 5-year, A$10 million contract to implement its Visage 7 Enterprise Imaging Platform at University Hospital Heidelberg and the German Cancer Research Institute, among other associated hospitals. This deal expands Pro Medicus’s presence in the European market, replacing and consolidating existing legacy systems to enhance diagnostic and research capabilities, thereby supporting cutting-edge medical research and patient care.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$333.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
More about Pro Medicus Limited
Pro Medicus Limited is a leading health imaging company that provides advanced imaging solutions through its European subsidiary, Visage Imaging. The company focuses on delivering ultrafast, scalable imaging platforms that consolidate legacy systems and streamline workflows, primarily serving the healthcare and biomedical research sectors.
Average Trading Volume: 175,371
Technical Sentiment Signal: Buy
Current Market Cap: A$31.79B
For an in-depth examination of PME stock, go to TipRanks’ Overview page.